You are here
P2D, INC
UEI: KX3EAX2JEMV8
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Efficacy of the Melatonin Agonist in the Treatment of Depression
Amount: $233,954.00DESCRIPTION (provided by applicant): P2D Inc. is developing a synthetic melatonin agonist, PD6735, for the treatment of depression. Preliminary Studies indicate that PD6735 produces an antidepressant- ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Ethanol Interactions of the Melatonin Agonist PD6735
Amount: $457,505.00DESCRIPTION (provided by applicant): CONFIDENTIAL. P2D, Inc. is developing the synthetic melatonin analog PD6735 as a treatment for insomnia. Insomnia is highly prevalent in the United States, affect ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Abuse Liability of the Melatonin Agonist PD6735
Amount: $250,000.00DESCRIPTION (provided by applicant): P2D, Inc. is developing a synthetic melatonin analog (PD6735) for treating sleep disorders and circadian rhythm disorders. Clinical studies suggest that PD6735 is ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
The Jaundice Chip: A diagnostic tool for cholestatic liver disease
Amount: $368,096.00DESCRIPTION (provided by applicant): Cholestasis (pathologic jaundice) is a very common sign of liver disease in children and adults, and results from genetic defects that play a critical role in bile ...
STTRPhase II2007Department of Health and Human Services National Institutes of Health -
Melatonin Analog PD6735 and Anxiety
Amount: $275,845.00DESCRIPTION (Provided by applicant): P2D, Inc. is developing a synthetic melatonin analog, PD6735, for the treatment of anxiety. Preliminary Studies suggest that PD6735 reduces anxiety in rodents. ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Neuroprotective efficacy of a melatonin analog in traumatic brain injury
Amount: $177,363.00DESCRIPTION (provided by applicant): The goal of this Phase 1 SBIR proposal is to determine whether the melatonin analog PD6735 (6-chloro- (R) B-methyl melatonin) is neuroprotective in a rat traumatic ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Jaundice Chip: Diagnostic tool for cholestatic liver dis
Amount: $206,027.00DESCRIPTION (provided by applicant): Cholestasis (or pathologic jaundice) is the most common sign of liver disease in children, and results from genetic defects in genes that play a critical role in b ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
Jaundice Chip: Diagnostic tool for cholestatic liver dis
Amount: $206,027.00DESCRIPTION (provided by applicant): Cholestasis (or pathologic jaundice) is the most common sign of liver disease in children, and results from genetic defects in genes that play a critical role in b ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Safety and Pharmacokinetics of PD6735 in the Elderly
Amount: $324,340.00DESCRIPTION (PROVIDED BY APPLICANT): Phase II Discovery, Inc. is developing a synthetic melatonin analog (PD6735) for treating sleep disorders that lacks the side effects of current first-line sleep ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
GIR Antagonists: Novel Feeding/Catabolism Molecules
Amount: $174,407.00DESCRIPTION (provided by applicant): Obesity has risen to epidemic proportions in the United States, contributing to over 52 billion USD per year in direct medical costs. Limited treatment options and ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health